Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 8;16:245–259. doi: 10.2147/TCRM.S243462

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Glaspy et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Hypophosphatemia rate (%) reported per RCT.

Notes: Reported hypophosphatemia rates are given as noted in Table 1. Corresponding sample size of study treatment arm is shown below each study title. *Breymann et al31 report 0% hypophosphatemia treatment-emergent adverse events in patients; however, this study reports serum phosphate levels below the threshold of CTCAE grade 3 hypophosphatemia in 8.1% of patients. Macdougall et al33 report no “clinically significant hypophosphatemia”; however this study reports phosphate decrease in supplemental figures but without detailed information on number or % of patients falling below CTCAE threshold.

Abbreviations: RCT, randomized controlled trial; IVI, intravenous iron; FCM, ferric carboxymaltose; LMW, low-molecular-weight.